close

References

1. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-425.
2. Boscoe AN, Xin H, LʼItalien GJ, Harris LA, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromusc Dis. 2019;20(4):173-181.
3. Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2020;10:3052.
4. Bird SJ. Pathogenesis of myasthenia gravis – UpToDate. www.uptodate.com/contents/pathogenesis-of-myasthenia-gravis. Accessed November 5, 2021.
5. Imai T. Why is development of new treatments necessary for myasthenia gravis? Recent advances in clinical trials. Neurol Clin Neurosci. 2019;7(4):161-165.